Our laboratory investigations have focused on the generation of tumor reactive T cells derived from lymph nodes (LNs) draining sites of progressive tumor or vaccines, and evaluating their anti-tumor reactivity. We have shown that these tumor-primed LNs can be secondarily activated in vitro by anti-CD3 as a surrogate antigen along with other costimulatory molecules (anti-CD28 and anti-4-1BB) to mature into potent effector cells that mediate tumor regression in adoptive immunotherapy. During the last funding period, we found that the in vitro activation of tumor-draining LN (TDLN) cells with an anti-CD3/anti-CD28/anti-4-1BB combination of mAbs resulted in polarization of the cytokine response mediated by the activated cells in response to tumor antigen. Polarized TDLN cells mediated a greater type 1 cytokine (i.e. IFNgamma) response and a decrease type 2 cytokine (ie. IL-4 and IL-10) response compared anti-CD3 activated TDLN cells. Furthermore, the polarized cells manifested significantly enhanced in vivo tumor regression upon adoptive transfer. Also, we have demonstrated that the in vivo administration of anti-4-1BB mAb resulted in the polarization of host lymphoid cells after tumor vaccination. This polarization augmented the therapeutic efficacy of DC-based vaccination in the treatment of established tumors. During the next funding period, we would like to investigate the mechanisms involved with 4-1BB co-stimulation of effector cells; develop additional activation methods to generate tumor-primed lymphoid cells; and, investigate the function of mature effector cells in the lymphopenic host.
The specific aims of this proposal are: 1. Examine the in vitro mechanisms of 4-1BB co-stimulation on the polarization of tumor-primed lymphoid cells. 2. Examine the in vivo mechanisms of 4-1BB co-stimulation in T cell immunotherapy. 3. Develop novel methods to activate and expand tumor-primed lymphoid cells. 4. Evaluate the function of adoptively transferred effector cells in the lymphopenic host. The information derived from these studies will provide important insights for the development of immunotherapeutic strategies for the treatment of cancer. We have extensive experience in the conduct of adoptive immunotherapy and vaccine trials in humans that will allow translation of these findings.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA082529-06
Application #
6819847
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Mccarthy, Susan A
Project Start
1999-09-01
Project End
2009-06-30
Budget Start
2004-07-12
Budget End
2005-06-30
Support Year
6
Fiscal Year
2004
Total Cost
$330,547
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Surgery
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Tao, Huimin; Lu, Lin; Xia, Yang et al. (2015) Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10. Eur J Immunol 45:999-1009
Li, Qiao; Lu, Lin; Tao, Huimin et al. (2014) Generation of a novel dendritic-cell vaccine using melanoma and squamous cancer stem cells. J Vis Exp :e50561
Wei, Shuang; Egenti, Martin U; Teitz-Tennenbaum, Seagal et al. (2013) Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice. J Immunother 36:124-32
Ning, Ning; Pan, Qin; Zheng, Fang et al. (2012) Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res 72:1853-64
Namm, Jukes P; Li, Qiao; Lao, Xiangming et al. (2012) B lymphocytes as effector cells in the immunotherapy of cancer. J Surg Oncol 105:431-5
Li, Qiao; Lao, Xiangming; Pan, Qin et al. (2011) Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res 17:4987-95
Teitz-Tennenbaum, Seagal; Li, Qiao; Davis, Mary A et al. (2009) Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer. J Immunother 32:602-12
Li, Qiao; Teitz-Tennenbaum, Seagal; Donald, Elizabeth J et al. (2009) In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J Immunol 183:3195-203
Teitz-Tennenbaum, Seagal; Li, Qiao; Davis, Mary A et al. (2008) Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model. Clin Immunol 129:482-91
Iuchi, Takekazu; Teitz-Tennenbaum, Seagal; Huang, Jianhua et al. (2008) Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses. Cancer Res 68:4431-41

Showing the most recent 10 out of 19 publications